Healthcare Industry News: ventilator
News Release - March 28, 2006
Gentium Receives First IRB Approval to Begin U.S. Phase III Trial with Defibrotide to Treat Veno-Occlusive Disease with Multiple-Organ FailureDana-Farber/Harvard Cancer Center, Massachusetts General Hospital, Beth Israel Deaconess Medical Center and The Children's Hospital Receive IRB Approval to Commence Study
VILLA GUARDIA (COMO), Italy--(HSMN NewsFeed)--March 28, 2006--Gentium S.p.A. (AMEX:GNT ; the Company) has received its first Institutional Review Board (IRB) approval to initiate a U.S. Phase III clinical trial with Defibrotide for the treatment of Veno-Occlusive Disease (VOD) with Multiple Organ Failure (Severe VOD) as a complication of stem cell transplantation (SCT). Data from this 80-patient, multi-center trial will be compared to an historical control group of 80 patients, with survival at day 100 as the primary endpoint. The Company believes that approximately 80% of patients with Severe VOD die within 100 days of SCT without treatment. The Company believes that there are no approved treatments for Severe VOD.
The IRB of the Dana-Farber/Harvard Cancer Center of Boston, Mass., which is also the IRB for Dana-Farber Cancer Institute, Massachusetts General Hospital, Beth Israel Deaconess Medical Center and The Children's Hospital, is the first to give its approval to commence the study. All four of these institutions are expected to participate in the trial. Work to compile historical control data will begin immediately, and the first patients are expected to be treated by early May 2006.
The multi-center trial will be conducted at approximately 20 U.S. cancer centers pending the IRB approval at each institution. In addition to the institutions mentioned above, the Company expects the trial to include M.D. Anderson Cancer Center, Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, Johns Hopkins Hospital and Health System, Duke University Hospital, City of Hope Cancer Center, The Children's Hospital of Philadelphia, University of Minnesota Medical Center and The St. Jude Children's Research Hospital, among others.
Paul Richardson, M.D., Clinical Director of Dana-Farber Cancer Institute's Jerome Lipper Multiple Myeloma Center and Assistant Professor of Medicine at Harvard Medical School, is the principal investigator of this Phase III trial. He recently presented Phase II data of Defibrotide as a treatment for Severe VOD at the 2005 American Society of Hematology (ASH) Annual Scientific Meeting. Commenting on the140-patient, multi-center, randomized, dose-finding Phase II study, Dr. Richardson said, "Treatment of Severe VOD with Defibrotide resulted in a survival rate at 100 days post SCT of approximately 40%, which compares favorably with the 100-day survival rate of approximately 20% or less reported in published studies of Severe VOD. These results are encouraging, with response and long-term survival seen even in patients who either were on dialysis or were ventilator-dependent at the start of Defibrotide therapy. In addition, the side effect profile of Defibrotide was favorable in this extremely sick patient population."
"As we continue to advance the development of Defibrotide, we are increasingly impressed by the consistency of the clinical findings and I am optimistic that we will soon be able to offer an effective treatment option for patients suffering from this otherwise often fatal disease," commented Laura Ferro, M.D., president and chief executive officer of Gentium. "We are pleased to initiate this U.S. Phase III study and hope to see compelling clinical results."
The U.S. Food and Drug Administration (FDA) has granted Defibrotide Orphan Drug Status and Fast Track designation for the treatment of Severe VOD. In addition, previous clinical trials with Defibrotide for the treatment of Severe VOD have been supported by grants from FDA's Office of Orphan Products Development.
VOD is a potentially life-threatening condition. Certain high dose chemotherapy and radiation therapies and stem cell transplantation (SCT) can damage cells of the blood vessels and result in VOD, a blockage of the small veins of the liver that can lead to liver failure and the failure of other organs (Severe VOD). SCT is a frequently used treatment following high dose chemotherapy and radiation therapy. The International Bone Marrow Transplant Registry estimated that approximately 45,000 people received blood and bone marrow transplants, which are types of SCT, in 2002. Based on the Company's review of more than 200 published papers, it believes that approximately 20% of patients who undergo SCT develop VOD, approximately one-third of those who develop VOD progress to multiple organ failure (Severe VOD), and approximately 80% of Severe VOD patients die within 100 days of the SCT. The Company believes that there are no approved therapies to treat or prevent VOD in the U.S or the EU.
Gentium S.p.A. is a biopharmaceutical company located in Villa Guardia (Como), Italy, that is focused on the research, discovery and development of drugs derived from DNA extracted from natural sources, and drugs that are synthetic derivatives, to treat and prevent a variety of vascular diseases and conditions related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate in the U.S., is an investigational drug that has been granted Orphan Drug status by the U.S. FDA to treat Severe VOD and Fast Track designation for the treatment of Severe VOD in recipients of stem cell transplants.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements." In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results may differ, possibly materially, from those anticipated in these forward-looking statements. For a discussion of some of the risks and important factors that could affect future results, see the discussion in our Prospectus filed with the Securities and Exchange Commission under Rule 424(b)(5) under the caption "Risk Factors."
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.